ARTICLE | Clinical News

Factor IX-albumin fusion protein: Phase I data

February 13, 2012 8:00 AM UTC

An open-label, international Phase I trial in 25 patients with severe hemophilia B showed that single IV injections of 25, 50 and 75 IU/kg rIX-FP were well tolerated with no serious adverse events rep...